CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	16.54	17.08	47.11	38.7	57.06	53.62
Short-Term Investments	4.28	13.69	4.23	9.87	9.31	0.63
Cash & Short-Term Investments	20.81	30.77	51.34	48.57	66.37	54.25
Cash Growth	-41.53%	-40.06%	5.69%	-26.82%	22.36%	-36.27%
Accounts Receivable	10.12	9.55	12.97	9.8	4.65	1.29
Other Receivables	1.03	0.59	-	-	-	-
Receivables	11.14	10.14	12.97	9.8	4.65	1.29
Inventory	12.93	15.88	6.14	1.91	1.36	4.54
Prepaid Expenses	2.27	2.56	2.98	1.69	1.65	1.42
Other Current Assets	-	-	-	-	-	3.22
Total Current Assets	47.15	59.34	73.42	61.97	74.03	64.72
Property, Plant & Equipment	12.4	11.63	13.23	21.82	10.76	9.69
Long-Term Investments	2.25	1.69	7.46	40.13	29.44	14.04
Other Intangible Assets	1.12	1.84	1.06	12.2	13.21	13.67
Other Long-Term Assets	0.7	0.77	1.06	2.18	0.3	0.5
Total Assets	63.62	75.27	96.23	138.3	127.73	102.63
Accounts Payable	1.76	4.44	3.29	2.22	3.26	5.11
Accrued Expenses	12.98	7.63	7.64	6.04	1.97	1.65
Short-Term Debt	-	-	-	-	1.29	-
Current Portion of Leases	-	0.73	0.87	1.06	0.94	1.18
Current Income Taxes Payable	-	-	1.9	-	-	-
Current Unearned Revenue	-	2.54	2.62	0.06	-	-
Other Current Liabilities	-	1.39	0.69	3.81	0.52	-
Total Current Liabilities	14.74	16.73	17.01	13.19	7.98	7.95
Long-Term Debt	19.12	18.9	-	-	-	-
Long-Term Leases	-	1.62	0.48	1.11	0.97	1.02
Long-Term Unearned Revenue	-	-	-	2.83	2.35	-
Other Long-Term Liabilities	15.91	13.87	11.82	13.22	12.87	-
Total Liabilities	49.77	51.1	29.3	30.34	24.16	8.97
Common Stock	0	0	0	0	1.24	0.98
Additional Paid-In Capital	712.6	695.79	691.77	696.22	658.25	606.69
Retained Earnings	-685.71	-660.82	-637.16	-605.64	-570.5	-523.91
Treasury Stock	-9.6	-9.6	-9.33	-8.03	-8.03	-8.03
Comprehensive Income & Other	-3.44	-1.2	-0.7	1.95	0.59	-2.73
Total Common Equity	13.85	24.17	44.57	84.5	81.54	73
Minority Interest	-	-	22.36	23.46	22.03	20.67
Shareholders' Equity	13.85	24.17	66.93	107.96	103.57	93.67
Total Liabilities & Equity	63.62	75.27	96.23	138.3	127.73	102.63
Total Debt	19.12	21.24	1.34	2.17	3.2	2.2
Net Cash (Debt)	1.69	9.53	49.99	46.41	63.18	52.05
Net Cash Growth	-95.25%	-80.94%	7.73%	-26.55%	21.39%	-37.76%
Net Cash Per Share	0.12	0.71	3.66	3.41	5.72	5.42
Filing Date Shares Outstanding	15.29	12.99	13.32	13.66	13.98	9.9
Total Common Shares Outstanding	15.29	13.38	13.46	13.98	12.39	9.78
Working Capital	32.41	42.62	56.42	48.78	66.05	56.78
Book Value Per Share	0.91	1.81	3.31	6.04	6.58	7.47
Tangible Book Value	12.73	22.33	43.51	72.3	68.33	59.32
Tangible Book Value Per Share	0.83	1.67	3.23	5.17	5.51	6.07
Machinery	-	6.68	1.24	1.73	1.62	0.92
Construction In Progress	-	0.02	5.73	12.1	1.19	-
Leasehold Improvements	-	7.19	7.16	1.13	0.99	0.79

Source: S&P Capital IQ. Standard template. Financial Sources.